1 CANCER AUTOVACCINE (CAV) New specific active anticancer agent From Science To Business 11-12...
Transcript of 1 CANCER AUTOVACCINE (CAV) New specific active anticancer agent From Science To Business 11-12...
1
CANCER AUTOVACCINE (CAV)CANCER AUTOVACCINE (CAV) New specific active anticancer agent New specific active anticancer agent
From Science To Business 11-12 October 2006, Kyiv
G.P.PotebnyaG.P.Potebnya Telephone : Telephone : 259-91-94; 259-08-75259-91-94; 259-08-75
E-mail : E-mail : [email protected]@onconet.kiev.ua
R.E.Kavetsky Institute of Experimental Pathology, Oncology and R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine Radiobiology, NAS of Ukraine
Kyiv 03022, UkraineKyiv 03022, Ukraine
2
Proprietary information statementProprietary information statement
The technology material presented in this talk is available for licensing or joint product development.
None of the slides contain any confidential or proprietary information.
3
Problem Description & Market NeedProblem Description & Market Need
Cancer Diseases (on 100 000 populations): In the world:In the world: 210210 Central and East Europe:Central and East Europe: 349349 Ukraine:Ukraine: 341341((162000 in year 2005)162000 in year 2005)
Russia:Russia: 314314
CAV could be used for treatment 125000 of CAV could be used for treatment 125000 of all cases of cancers in Ukraine.all cases of cancers in Ukraine.
4
Brief technology descriptionBrief technology description prof. D.G.Zatula
CAV prepared from autologous tumor CAV prepared from autologous tumor cells and products of synthesis of a cells and products of synthesis of a saprophytic microorganism B.subtilis B-saprophytic microorganism B.subtilis B-7025;7025;
CAV introduced by hypodermic CAV introduced by hypodermic injections. The complete course consists injections. The complete course consists of 3 injections with 7 day's interval. The of 3 injections with 7 day's interval. The revaccination will be carried out through revaccination will be carried out through 1 and 6 months;1 and 6 months;
CAV prevented relapses and metastasis CAV prevented relapses and metastasis after surgery treatment, after surgery treatment, increased increased overall and relapse-free survival of overall and relapse-free survival of patients;patients;
CAV is recommended as independent CAV is recommended as independent immunotherapeutic agent in the immunotherapeutic agent in the postoperative period.postoperative period.
5
AdvantagesAdvantages
1.1. Wide specter cancer’s forms, where CAV treatment could be Wide specter cancer’s forms, where CAV treatment could be used.used.
2.2. CAV produced from own cells of patients, so there is no any CAV produced from own cells of patients, so there is no any risk of SPID, or other’s infection diseases and it’s need no risk of SPID, or other’s infection diseases and it’s need no control methods concerning alien infection agents.control methods concerning alien infection agents.
3.3. CAV is most effective at the late stages of cancer. CAV is most effective at the late stages of cancer. 4.4. Effectiveness of CAV treatment may be compared, or better, Effectiveness of CAV treatment may be compared, or better,
then chemo- or radiotherapy, but without so characteristic for then chemo- or radiotherapy, but without so characteristic for them toxic effects.them toxic effects.
5.5. Cost of production and treatment by CAV more lower then Cost of production and treatment by CAV more lower then chemo- or radiotherapy. chemo- or radiotherapy.
6.6. Combination to other methods of therapy:Combination to other methods of therapy:• After radical operation (early stages of disease, the absence
of metastasis) an effective utilization CAV without chemo- or radiotherapy. If it is necessary carryings out courses of chemo- or the radiotherapies immunotherapy by CAV may be started in 18-21 days after their end.
6
EFFICACY ANTICANCER AUTOVACCINE DURING EFFICACY ANTICANCER AUTOVACCINE DURING COMPLEX THERAPY IN STOMACH CANCER COMPLEX THERAPY IN STOMACH CANCER
PATIENTSPATIENTS ( (Overall survival)Overall survival)
• CAV treatment CAV treatment enhanced 5-years enhanced 5-years survival (57% versus survival (57% versus 31%), 10-years 31%), 10-years survival (50% versus survival (50% versus 27%); 27%);
• CAV treatment of CAV treatment of stomach cancer stomach cancer patients has no patients has no analogous.analogous.
0
10
20
30
40
50
60
Nu
mb
er
of
pa
tie
nts
, %
5 10years
Stomach cancer, stage ІІІ
Operation+Vaccine
Operation
7
EFFICACY ANTICANCER AUTOVACCINE DURING EFFICACY ANTICANCER AUTOVACCINE DURING COMPLEX THERAPY IN LUNG CANCER PATIENTSCOMPLEX THERAPY IN LUNG CANCER PATIENTS
((Overall survival)Overall survival)
• CAV treatment CAV treatment enhanced 5-years enhanced 5-years survival (39% versus survival (39% versus 10%);10%);
• CAV treatment of lung CAV treatment of lung cancer patients has no cancer patients has no analogousanalogous
0
10
20
30
40
50
60
Nu
mb
er
of
pa
tie
nts
,%
3 5
years
Lung cancer, stage ІІІА
Operation+Vaccine
Operation
8
Stage of development (clinical tests if Stage of development (clinical tests if medical) and international patentsmedical) and international patents
CAV treatment were supported by National Academy CAV treatment were supported by National Academy of Science of Ukraine, Ministry of Health and of Science of Ukraine, Ministry of Health and Farmcommittee of UkraineFarmcommittee of Ukraine
It was obtained permission (certificate) for using CAV It was obtained permission (certificate) for using CAV in Ukraine’s clinicsin Ukraine’s clinics
Now 8 clinics in country successfully use this Now 8 clinics in country successfully use this treatmenttreatment
9
Targeted Market SegmentTargeted Market Segment
• CAV could be used for treatment of most CAV could be used for treatment of most spread cancers formsspread cancers forms
Among them:
For menFor men:: For women:For women:
Lung cancer - 21% Breast cancer - 21%
Stomach cancer- 10% Cervical cancer - 6%
Rectum cancer- 6% Rectum cancer- 5%
Colon cancer- 5% Colon cancer - 6%
10
In comparison with existing products or methodsIn comparison with existing products or methodsSummary of 5-year' s survivals patients with rectum cancer
(III stage), who were undertaken different forms of treatments
Treated patientsTreated patients Overall Overall survivalsurvival
Relapse-free Relapse-free survivalsurvival
SurgerySurgery 29,0%29,0% 19,6%19,6%
Surgery+ radiotherapySurgery+ radiotherapy 42,7%42,7% 34,0%34,0%
Surgery Surgery +Chemotherapy+Chemotherapy
50,0%50,0% 30,0%30,0%
Surgery Surgery +Chemotherapy+CAV+Chemotherapy+CAV
77,0%77,0% 30,0%30,0%
Surgery +CAVSurgery +CAV 63,0%63,0% 38,0%38,0%
11
Competitive MatrixCompetitive MatrixIn comparison with another autologous anticancer
vaccines (colon cancer –5 years survival)
Characteristics R.E.Kavetsky R.E.Kavetsky Institute National Institute National
Academy of Academy of Sciense, Kiev, Sciense, Kiev,
UkraineUkraine
Massachusetts Massachusetts General Hospital, General Hospital,
BostonBoston, USA, USA
Department of Department of Oncology, Oncology, University University
Hospital, Hospital, Antwerp, Antwerp, Belgium. Belgium.
Overall survival 78%78% 83% 78%
Cost 100 $ 100 $ 5000-30000 $ 5000-30000 $
Side effects 10-20%10-20% 30-40% 70-90%
Components of vaccine
Tumor antigens Tumor antigens +cytotoxic lectin +cytotoxic lectin B.subtilisB.subtilis
Living irradiated Living irradiated tumor cells+ tumor cells+ living BCGliving BCG
Living irradiated Living irradiated tumor cells+ tumor cells+ living BCGliving BCG
12
OpportunitiesOpportunities
1. In common work to obtain licences for1. In common work to obtain licences for
CAV treatment in EC countries, USA and CAV treatment in EC countries, USA and RussiaRussia
2. In common work to produce and use2. In common work to produce and use
CAV in this countriesCAV in this countries
13
Contact information
G.P.Potebnya
Telephone : 259-91-94; 259-08-75
E-mail : [email protected]
R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Science, Ukraine